Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma
Yıl: 2019 Cilt: 29 Sayı: 4 Sayfa Aralığı: 210 - 218 Metin Dili: İngilizce DOI: 10.4999/uhod.193630 İndeks Tarihi: 29-06-2020
Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma
Öz: The aim of this study to demonstrate and compare the CXCR4 expression by means of 68Ga-Pentixafor PET/CT in patients withmultiple myeloma with standard clinical parameters and 18F-FDG PET/CT findings. Twenty-four (17 women, 7 men; mean age:58.9±12.7) multiple myeloma patients who had undergone 18F-FDG PET/CT imaging to evaluate the disease activity were included inthe study. 68Ga-Pentixafor PET/CT imaging was performed within an average period of 12 days after initial 18F-FDG PET/CT imaging.68Ga-Pentixafor PET and 18F-FDG PET/CT revealed focal pathological lesions in 13/24 (54%) and 16/24 (67%) patients, respectively.In 19/24 patients, both tracers showed concordant findings (CXCR4+ and FDG+ in 12 patients; CXCR4- and FDG- in 7patients).In the remaining 5 patients, findings were discordant. The number of focal lesions identified by means of 68Ga-Pentixafor and 18FFDG were 89 (44%) and 113 (56%), respectively. 68Ga-Pentixafor PET/CT showed more lesions in 2/12 (17%) patients, whereas18F-FDG PET/CT was proved to be superior in 7/12 (58%) patients. In the remaining 3/12 (25%) patients, both tracers detected anequal number of lesions. There was no significant difference in appendicular and axial skeletal and extramedullary distribution ratiosfor both PET/CT examinations (p> 0.05). There was no statistically significant correlations between the 68Ga-Pentixafor PET/CT and18F-FDG PET/CT positivity and disease activity, MM subtype, ISS phase, light chain disease, beta2microglobulin, albumin, creatinine,LDH, FLC and M protein levels in during scans. 68Ga-Pentixafor PET/CT cannot replace 18F-FDG PET/CT for diagnostic imaging ofpatients with multiple myeloma, 68Ga-PET/CT seem to be a valuable probe for patient stratification in the context of CXCR4-targetedradioligand therapy.
Anahtar Kelime: Multipl Myelomalı Hastalarda Kemokin Reseptör-4 Ekspresyonunun Ga-68 Pentiksafor PET/BT ile Değerlendirilmesi
Öz: Bu çalışmanın amacı, multipl myelomalı hastalarda CXCR4 ekspresyonun Ga-68 PSMA Pentiksafor PET/BT ile gösterilmesi ve standart klinik parametreler ve 18F-FDG PET/BT bulguları ile karşılaştırılmasıdır. Çalışmaya multipl myelom tanısı ile hastalık aktivitesinin değerlendirilmesi amacıyla 18F-FDG PET/BT yapılan yirmi dört (17 kadın, 7 erkek; ort yaş: 58.9±12.7) hasta dahil edildi. Ga-68 Pentiksafor PET/BT, 18F-FDG PET/BT’yi takiben ortalama 12 günlük süre içinde uygulandı. Ga-68 Pentiksafor PET ve 18F-FDG PET/ BT, sırası ile 13/24 (%54) ve 16/24 (%67) hastada fokal patolojik lezyonları gösterdi. 19/24 hastada her iki yöntem uyumlu bulgular 12 hastada CXCR4 ve FDG+; 7 hastada CXCR4 ve FDG- gösterdi. Geri kalan 5 hastada ise bulgular uyumsuzdu. Ga-68 pentiksafor ve 18F-FDG PET ile ortaya konulan fokal lezyon sayısı sırası ile 89 (%44) and 113 (%56) idi. 2/12 (%17) hastada Ga-68 Pentiksafor PET/ BT daha fazla sayıda lezyon gösterirken, 7/12 (%58) hastada 18F-FDG PET/BT üstündü. Geri kalan 3/12 (%25) hastada ise her iki yöntem benzer sayıda lezyon gösterdi. Her iki yöntem ile saptanan apendiküler, aksiyel iskelet ve ekstramedüller lezyonların dağılımı arasındaki fark anlamlı değildi (p> 0.05). Ga-68 Pentiksafor ve 18F-FDG PET/BT pozitifliği ile hastalık aktivitesi, MM alt tipi, ISS fazı, hafif zincir hasalığı, beta2 mikroglobulin, albumin, kreatinin, LDH, FLC ve M protein düzeyleri arasında anlamlı ilişki saptanmadı. Ga-68 Pentiksafor PET/BT multipl myelomalı hastalarda tanısal görüntüleme yöntemi olarak 18FFDG PET/BT nin yerini alamaz, Ga-68 Pentiksafor PET/BT, CXCR-4 hedefli radyoligand tedavi planlanan hastalarda hasta seçimi amacıyla faydalı olabilir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-spesific metastasis. Nat Rev Immunol 11: 597-606, 2011.
- 2. Jacobson O, Weiss ID. CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics 3: 1-2, 2013.
- 3. Ratajczak MZ, Serwin K, Schneider G. Innate Immunity Derived Factors as External Modulators of the CXCL12 - CXCR4 Axis and Their Role in Stem Cell Homing and Mobilization. Theranostics 3: 3-10, 2013.
- 4. Palumbo A, Anderson K. Multiple myeloma. N Eng J Med 364: 1046-1060, 2011.
- 5. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28: 525-542, 2014.
- 6. Zannettino ACW, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65: 1700-1709, 2005.
- 7. Bao L, Lai Y, Liu Y, et al. CXCR4 is a good survival prognostic indicator in multiple myeloma. Leuk Res 37: 1083- 1088, 2013.
- 8. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767, 2006.
- 9. Demmer O, Gourni E, Schumacher U, et al. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. Chem Med Chem 6: 1789-1791, 2011.
- 10. Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 52: 1803-1810, 2011.
- 11. Herrman K, Lapa C, Wester HJ, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4- targeting probe 68Ga-Pentixafor. J Nucl Med 56: 410- 416, 2015.
- 12. Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemocine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine 7: 477-487, 2015.
- 13. Lapa C, Schreder M, Schirbel A, et al. 68GaPentixaforPET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma – Comparison to 18F-FDG and laboratory values. Theranostics 7: 205-212, 2017.
- 14. Mesguich C, Zanotti-Fregonara P, Hindie E. New perspective offered by Nuclear Medicine for the imaging and therapy of multiple myeloma. Theranostics 6: 287-290, 2016.
- 15. Herrmann K, Schottelius M, Lapa C, et al. First-in-Human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57: 248-251, 2015.
- 16. Walenkamp AME, Lapa C, Herrmann K, Wester HJ. CXCR4 ligands: the next big hit? J Nucl Med 2017 58: 77-82, 2017.
- 17. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/ CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement bt the International Myeloma Working Group. Lancet Oncol 18: 206-217, 2017.
- 18. Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45: 712-719, 2018.
- 19. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010 16: 2927-2977, 2010.
- 20. Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 20: 833-846, 2014.
- 21. Shain KH, Tao J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene 33: 4107-4113, 2014.
- 22. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92: 50-55, 2007.
- 23. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118: 5989-5995, 2011.
| APA | Ozkan E, Soydal C, Sahin U, Beksac M, Öztürk C, civriz bozdag s, Topcuoglu P, Kropf S, Wester H, kucuk n (2019). Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. , 210 - 218. 10.4999/uhod.193630 |
| Chicago | Ozkan Elgin,Soydal Cigdem,Sahin Ugur,Beksac Meral,Öztürk Cemaleddin,civriz bozdag sinem,Topcuoglu Pervin,Kropf Saskia,Wester Hans-Juergen,kucuk nuriye ozlem Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. (2019): 210 - 218. 10.4999/uhod.193630 |
| MLA | Ozkan Elgin,Soydal Cigdem,Sahin Ugur,Beksac Meral,Öztürk Cemaleddin,civriz bozdag sinem,Topcuoglu Pervin,Kropf Saskia,Wester Hans-Juergen,kucuk nuriye ozlem Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. , 2019, ss.210 - 218. 10.4999/uhod.193630 |
| AMA | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. . 2019; 210 - 218. 10.4999/uhod.193630 |
| Vancouver | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. . 2019; 210 - 218. 10.4999/uhod.193630 |
| IEEE | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n "Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma." , ss.210 - 218, 2019. 10.4999/uhod.193630 |
| ISNAD | Ozkan, Elgin vd. "Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma". (2019), 210-218. https://doi.org/10.4999/uhod.193630 |
| APA | Ozkan E, Soydal C, Sahin U, Beksac M, Öztürk C, civriz bozdag s, Topcuoglu P, Kropf S, Wester H, kucuk n (2019). Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. Uluslararası Hematoloji-Onkoloji Dergisi, 29(4), 210 - 218. 10.4999/uhod.193630 |
| Chicago | Ozkan Elgin,Soydal Cigdem,Sahin Ugur,Beksac Meral,Öztürk Cemaleddin,civriz bozdag sinem,Topcuoglu Pervin,Kropf Saskia,Wester Hans-Juergen,kucuk nuriye ozlem Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. Uluslararası Hematoloji-Onkoloji Dergisi 29, no.4 (2019): 210 - 218. 10.4999/uhod.193630 |
| MLA | Ozkan Elgin,Soydal Cigdem,Sahin Ugur,Beksac Meral,Öztürk Cemaleddin,civriz bozdag sinem,Topcuoglu Pervin,Kropf Saskia,Wester Hans-Juergen,kucuk nuriye ozlem Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. Uluslararası Hematoloji-Onkoloji Dergisi, vol.29, no.4, 2019, ss.210 - 218. 10.4999/uhod.193630 |
| AMA | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. Uluslararası Hematoloji-Onkoloji Dergisi. 2019; 29(4): 210 - 218. 10.4999/uhod.193630 |
| Vancouver | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma. Uluslararası Hematoloji-Onkoloji Dergisi. 2019; 29(4): 210 - 218. 10.4999/uhod.193630 |
| IEEE | Ozkan E,Soydal C,Sahin U,Beksac M,Öztürk C,civriz bozdag s,Topcuoglu P,Kropf S,Wester H,kucuk n "Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma." Uluslararası Hematoloji-Onkoloji Dergisi, 29, ss.210 - 218, 2019. 10.4999/uhod.193630 |
| ISNAD | Ozkan, Elgin vd. "Evaluation of Chemokine Receptor-4 Expression by 68Ga – Pentixafor PET/CT in Patients with Multiple Myeloma". Uluslararası Hematoloji-Onkoloji Dergisi 29/4 (2019), 210-218. https://doi.org/10.4999/uhod.193630 |
